Cigarette smoke extract increases C5a receptor expression in human bronchial epithelial cells.
We have shown that exposing human bronchial epithelial cells (HBECs) to 5% cigarette smoke extract (CSE) up-regulates C5a anaphylatoxin receptor (C5aR) expression as determined by flow cytometric analysis and immunohistochemistry. In this study, we conducted whole-cell saturation studies to quantitate the receptor number. After exposing an HBEC line (BEAS-2B) to CSE, radiolabeled C5a bound saturably with Kd = 2.71 +/- 1.03 nM (n = 4) and Bmax = 15,044 +/- 5702 receptors/cells. Without 5% CSE, no C5a binding was detected. Competitive binding studies revealed two classes of sites with distinct affinities for C5a (Ki1 = 3.28 x 10(-16) M; Ki2 = 1.60 x 10(-9) M). BEAS-2Bs were transfected with wild-type (WT) or mutant dominant-negative (DN) protein kinase C-alpha (PKC-alpha) to investigate the relationship between PKC-alpha and C5aR availability and affinity. Western blot analysis revealed a 75-kDa lysate band from cells expressing WT and DN PKC-alpha, but DN cells exposed to 5% CSE had no functional PKC activity. Pretreatment with Gö6976 [12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo(2,3-a)pyrrolo(3,4-c)-carbazole] (PKC-alpha inhibitor) had no effect on DN but significantly decreased WT PKC activity. Competitive binding studies conducted on either WT or DN PKC-alpha-transfected cells also revealed two classes of binding sites for C5a having different affinities. There was a significant rightward shift of the binding curve when WT cells were pretreated with Gö6976. These data suggest that C5aR is detectable on bronchial epithelial cells exposed to CSE and that exposure to CSE increases the availability of C5a binding sites. The data also indicate that PKC-alpha may play an important role in modulating C5aR binding.
Allen-Gipson
Diane S
DS
Pulmonary, Critical Care, and Sleep Medicine Section, Department of Internal Medicine, University of Nebraska Medical Center, 985815 Nebraska Medical Center, Omaha, NE 68198-5815, USA. dallengipson@unmc.edu
Floreani
Anthony A
AA
Heires
Art J
AJ
Sanderson
Sam D
SD
MacDonald
Richard G
RG
Wyatt
Todd A
TA
D001667:Binding, Competitive / Q000187:drug effects; D015153:Blotting, Western; D001980:Bronchi / Q000187:drug effects / Q000378:metabolism*; D002227:Carbazoles / Q000494:pharmacology; D015936:Complement C5a / Q000378:metabolism; D004591:Electrophoresis, Polyacrylamide Gel; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004847:Epithelial Cells / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007211:Indoles / Q000494:pharmacology; D007457:Iodine Radioisotopes; D011493:Protein Kinase C / Q000037:antagonists & inhibitors / Q000378:metabolism; D051571:Protein Kinase C-alpha; D011869:Radioligand Assay; D044087:Receptor, Anaphylatoxin C5a / Q000096:biosynthesis* / Q000235:genetics; D011994:Recombinant Proteins / Q000187:drug effects; D012906:Smoke / Q000032:analysis*; D014026:Nicotiana; D014162:Transfection
D002227:Carbazoles; D004791:Enzyme Inhibitors; D007211:Indoles; D007457:Iodine Radioisotopes; D044087:Receptor, Anaphylatoxin C5a; D011994:Recombinant Proteins; D012906:Smoke; C081021:Go 6976; D015936:Complement C5a; C496628:PRKCA protein, human; D011493:Protein Kinase C; D051571:Protein Kinase C-alpha